SCHEMBL19966360

SCHEMBL19966360

CC(C)(C)OC(=O)NC12CCC(COS(=O)(=O)c3ccc(C(F)(F)F)cc3)(CC1)CC2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.42
MAPT P10636 1/20 0.36
MMP2 P08253 3/20 0.36
MMP3 P08254 3/20 0.36
MMP9 P14780 3/20 0.36
MMP8 P22894 3/20 0.36
MMP13 P45452 3/20 0.36
MMP14 P50281 3/20 0.36
TGFBR1 P36897 1/20 0.36
MAOB P27338 1/20 0.36
ENPP3 O14638 4/20 0.35
ENPP1 P22413 3/20 0.35
ENPP2 Q13822 3/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
MMP1 P03956 3/20 0.35
GAA P10253 1/20 0.34
EEF2K O00418 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19953298 0.94 RORC (0.41) RORCMAPTMMP2MMP3MMP9
SCHEMBL19953326 0.90 RORC (0.41) RORCMAPTMMP2MMP3MMP9
SCHEMBL19953317 0.84 RORC (0.39) RORCMAPTMMP2MMP3MMP9
SCHEMBL19953318 0.81 TRPV4 (0.34) RORCMAPTMMP2MMP3MMP9
SCHEMBL20271345 0.78 MEN1 (0.34)
SCHEMBL30103240 0.77 STAT3 (0.39) RORCMMP13MAOB
SCHEMBL19953443 0.75 FOLH1 (0.33) RORCMAOB
SCHEMBL19966589 0.73 CA12 (0.43) MAPTMMP2MMP3MMP9MMP13
SCHEMBL14842193 0.73 STAT3 (0.40) RORCMMP13MAOB
SCHEMBL23329361 0.73 MAOB (0.49) MMP2MMP13MMP14MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210101902-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2021-04-08 US disclosed
US-10954233-B2 Compounds and compositions as inhibitors of endosomal toll-like receptors NOVARTIS AG (CH) 2021-03-23 US disclosed
US-20190211009-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2019-07-11 US disclosed
WO-2018047081-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS NOVARTIS AG (CH) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210101902-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 RORC 154/4885MAPT 2938/4885MMP2 4406/4885
US-20190211009-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS TLR3, TLR1, TLR4 RORC 154/4885MAPT 2938/4885MMP2 4406/4885
US-10954233-B2 Compounds and compositions as inhibitors of endosomal toll-like receptors TLR3, TLR1, TLR4 RORC 154/4885MAPT 2938/4885MMP2 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.